SCHEMBL4841863

SCHEMBL4841863

Cc1nc(Oc2ccccc2)c([N+](=O)[O-])c(NCCOCc2ccncc2)c1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ATM Q13315 1/20 0.38
LMNA P02545 4/20 0.37
TP53 P04637 1/20 0.37
MGMT P16455 2/20 0.36
FES P07332 1/20 0.34
FGFR1 P11362 1/20 0.34
FLT4 P35916 1/20 0.34
KDR P35968 1/20 0.34
F2 P00734 1/20 0.33
GBA1 P04062 1/20 0.32
ALDH1A1 P00352 1/20 0.32
EGFR P00533 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MAPT P10636 1/20 0.32
GAA P10253 2/20 0.32
HTT P42858 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4766860 0.94 LMNA (0.41) NPC1RAB9AMEN1KMT2AATM
SCHEMBL4773614 0.84 MAPT (0.47) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL4775733 0.83 FES (0.35) LMNAFESFGFR1FLT4KDR
SCHEMBL4773502 0.83 MGMT (0.38) LMNATP53MGMTF2GBA1
SCHEMBL4775513 0.82 LMNA (0.37) NPC1RAB9AMEN1KMT2AATM
SCHEMBL4776209 0.81 LMNA (0.41) LMNATP53MGMTGBA1ALDH1A1
SCHEMBL5333576 0.81 MAPT (0.42) RAB9AMEN1KMT2ALMNATP53
SCHEMBL4835830 0.81 KDM4E (0.39) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL4829956 0.80 MAPT (0.41) MEN1KMT2ALMNATP53ALDH1A1
SCHEMBL4769141 0.79 POLB (0.40) MEN1KMT2ALMNATP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513524-A4 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES CO (US) 2008-09-03 EP disclosed
US-7220758-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-22 US disclosed
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2006-11-09 US disclosed
US-7125890-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-10-24 US disclosed
EP-1513524-A2 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M Innovative Properties Company (US) 2005-03-16 EP disclosed
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors 3M INNOVATIVE PROPERTIES COMPANY 2005-02-10 US disclosed
US-6797718-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-09-28 US disclosed
US-20040010007-A1 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-01-15 US disclosed
WO-2003103584-A2 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES IL2, IL4, MYD88 NPC1 3237/4885RAB9A 3015/4885MEN1 3243/4885
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors IL2, IFNG, TSLP NPC1 3418/4885RAB9A 2659/4885MEN1 2247/4885
US-20040010007-A1 Ether substituted imidazopyridines IL2, IL4, MYD88 NPC1 3237/4885RAB9A 3015/4885MEN1 3243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.